Nobilon acquired rights from Vivalis to its EBx® cell lines and related technology platform. The cell lines, which are derived from avian embryonic stem cells, along with the technology, will be used to develop, produce, and market human influenza vaccines, including seasonal and pandemic.
This worldwide, nonexclusive license deal includes an upfront payment, milestones, and royalties.
“All human influenza vaccines currently available on the market are produced on chicken eggs,” notes Han van den Bosch, director R&D at Nobilon. “Nobilon already utilizes modern cell culture production, which has major advantages over egg production. We have several vaccines produced on mammalian cells in various stages of development. The Vivalis EBx avian cell line provides us with additional means for influenza vaccine production in the near future.”